Abstract
OBJECTIVE: Tamoxifen is commonly used for the adjuvant treatment after chemotherapy or metastatic disease in women with hormone receptor-positive breast cancer. Clinical profiles during tamoxifen therapy have not been evaluated in patients who took GnRH agonist injection for ovarian protection. Therefore, this study was conducted to evaluate menstrual patterns, hormonal profiles and endometrial effects in tamoxifen-treated premenopausal breast cancer patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
